← FDA DRUG APPROVALS

FDA NDA · NDA020338

DIFFERIN

Sponsor: GALDERMA LABS LP

APPLICATION
NDA020338
TYPE
NDA
ORIGINAL APPROVAL
1996-05-31
LATEST ACTION
2002-04-08
ROUTE
TOPICAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued

Products

DIFFERIN · ReferenceDiscontinued
ADAPALENE 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION · TOPICAL

Approval history

2002-04-08Manufacturing (CMC) · Supplement 3 · standardAP
1999-09-10Manufacturing (CMC) · Supplement 2 · standardAP
1998-11-12Manufacturing (CMC) · Supplement 1 · standardAP
1996-05-31Type 1 - New Molecular Entity · Original · standard — Review ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →